These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 22289989)

  • 41. Bioinformatic analysis of the effects and mechanisms of decitabine and cytarabine on acute myeloid leukemia.
    Zhou S; Liu P; Zhang H
    Mol Med Rep; 2017 Jul; 16(1):281-287. PubMed ID: 28498449
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chemotherapy-induced differential cell cycle arrest in B-cell lymphomas affects their sensitivity to Wee1 inhibition.
    Wang X; Chen Z; Mishra AK; Silva A; Ren W; Pan Z; Wang JH
    Haematologica; 2018 Mar; 103(3):466-476. PubMed ID: 29217775
    [TBL] [Abstract][Full Text] [Related]  

  • 43. WEE1 accumulation and deregulation of S-phase proteins mediate MLN4924 potent inhibitory effect on Ewing sarcoma cells.
    Mackintosh C; García-Domínguez DJ; Ordóñez JL; Ginel-Picardo A; Smith PG; Sacristán MP; de Álava E
    Oncogene; 2013 Mar; 32(11):1441-51. PubMed ID: 22641220
    [TBL] [Abstract][Full Text] [Related]  

  • 44. WEE1 inhibition sensitizes osteosarcoma to radiotherapy.
    PosthumaDeBoer J; Würdinger T; Graat HC; van Beusechem VW; Helder MN; van Royen BJ; Kaspers GJ
    BMC Cancer; 2011 Apr; 11():156. PubMed ID: 21529352
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage.
    Xie C; Edwards H; Caldwell JT; Wang G; Taub JW; Ge Y
    Mol Oncol; 2015 Feb; 9(2):409-21. PubMed ID: 25308513
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death.
    Heo SK; Noh EK; Yu HM; Kim DK; Seo HJ; Lee YJ; Cheon J; Koh SJ; Min YJ; Choi Y; Jo JC
    BMC Cancer; 2020 Dec; 20(1):1193. PubMed ID: 33276759
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51.
    Xie C; Drenberg C; Edwards H; Caldwell JT; Chen W; Inaba H; Xu X; Buck SA; Taub JW; Baker SD; Ge Y
    PLoS One; 2013; 8(11):e79106. PubMed ID: 24244429
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading.
    Hauge S; Naucke C; Hasvold G; Joel M; Rødland GE; Juzenas P; Stokke T; Syljuåsen RG
    Oncotarget; 2017 Feb; 8(7):10966-10979. PubMed ID: 28030798
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses.
    Stewart E; McEvoy J; Wang H; Chen X; Honnell V; Ocarz M; Gordon B; Dapper J; Blankenship K; Yang Y; Li Y; Shaw TI; Cho JH; Wang X; Xu B; Gupta P; Fan Y; Liu Y; Rusch M; Griffiths L; Jeon J; Freeman BB; Clay MR; Pappo A; Easton J; Shurtleff S; Shelat A; Zhou X; Boggs K; Mulder H; Yergeau D; Bahrami A; Mardis ER; Wilson RK; Zhang J; Peng J; Downing JR; Dyer MA;
    Cancer Cell; 2018 Sep; 34(3):411-426.e19. PubMed ID: 30146332
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine.
    Mesa RA; Loegering D; Powell HL; Flatten K; Arlander SJ; Dai NT; Heldebrant MP; Vroman BT; Smith BD; Karp JE; Eyck CJ; Erlichman C; Kaufmann SH; Karnitz LM
    Blood; 2005 Jul; 106(1):318-27. PubMed ID: 15784732
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.
    Carrassa L; Chilà R; Lupi M; Ricci F; Celenza C; Mazzoletti M; Broggini M; Damia G
    Cell Cycle; 2012 Jul; 11(13):2507-17. PubMed ID: 22713237
    [TBL] [Abstract][Full Text] [Related]  

  • 52. BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
    Schwind S; Marcucci G; Maharry K; Radmacher MD; Mrózek K; Holland KB; Margeson D; Becker H; Whitman SP; Wu YZ; Metzeler KH; Powell BL; Kolitz JE; Carter TH; Moore JO; Baer MR; Carroll AJ; Caligiuri MA; Larson RA; Bloomfield CD
    Blood; 2010 Dec; 116(25):5660-9. PubMed ID: 20841507
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways.
    Hassane DC; Sen S; Minhajuddin M; Rossi RM; Corbett CA; Balys M; Wei L; Crooks PA; Guzman ML; Jordan CT
    Blood; 2010 Dec; 116(26):5983-90. PubMed ID: 20889920
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia.
    Hu XF; Slater A; Kantharidis P; Rischin D; Juneja S; Rossi R; Lee G; Parkin JD; Zalcberg JR
    Blood; 1999 Jun; 93(12):4086-95. PubMed ID: 10361105
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia.
    Degwert N; Latuske E; Vohwinkel G; Stamm H; Klokow M; Bokemeyer C; Fiedler W; Wellbrock J
    Eur J Haematol; 2016 Sep; 97(3):239-44. PubMed ID: 26613208
    [TBL] [Abstract][Full Text] [Related]  

  • 56. miR-15a-5p and miR-21-5p contribute to chemoresistance in cytogenetically normal acute myeloid leukaemia by targeting PDCD4, ARL2 and BTG2.
    Vandewalle V; Essaghir A; Bollaert E; Lenglez S; Graux C; Schoemans H; Saussoy P; Michaux L; Valk PJM; Demoulin JB; Havelange V
    J Cell Mol Med; 2021 Jan; 25(1):575-585. PubMed ID: 33270982
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Whole-Genome Expression Microarray Combined with Machine Learning to Identify Prognostic Biomarkers for High-Grade Glioma.
    Shu C; Wang Q; Yan X; Wang J
    J Mol Neurosci; 2018 Apr; 64(4):491-500. PubMed ID: 29502292
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes.
    Lamba JK; Crews KR; Pounds SB; Cao X; Gandhi V; Plunkett W; Razzouk BI; Lamba V; Baker SD; Raimondi SC; Campana D; Pui CH; Downing JR; Rubnitz JE; Ribeiro RC
    Pharmacogenomics; 2011 Mar; 12(3):327-39. PubMed ID: 21449673
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells.
    Xu X; Xie C; Edwards H; Zhou H; Buck SA; Ge Y
    PLoS One; 2011 Feb; 6(2):e17138. PubMed ID: 21359182
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR.
    Handschuh L; Kaźmierczak M; Milewski MC; Góralski M; Łuczak M; Wojtaszewska M; Uszczyńska-Ratajczak B; Lewandowski K; Komarnicki M; Figlerowicz M
    Int J Oncol; 2018 Mar; 52(3):656-678. PubMed ID: 29286103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.